Wave Life Sciences, Inc. (WVE)
| Market Cap | 708.05M -46.1% |
| Revenue (ttm) | 70.92M -35.1% |
| Net Income | -210.53M |
| EPS | -1.07 |
| Shares Out | 197.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,330,982 |
| Open | 3.620 |
| Previous Close | 3.630 |
| Day's Range | 3.430 - 3.700 |
| 52-Week Range | 3.040 - 21.730 |
| Beta | -1.43 |
| Analysts | Strong Buy |
| Price Target | 17.11 (+376.6%) |
| Earnings Date | Oct 27, 2026 |
About WVE
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscula... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $17.11, which is an increase of 376.60% from the latest price.
News
Wave Life Sciences price target raised to $44 from $42 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on Wave Life Sciences (WVE) to $44 from $42 and keeps a Buy rating on the shares. The firm said they…
Wave Life Sciences has ‘catalyst-rich stretch’ ahead, says H.C. Wainwright
After Wave Life Sciences (WVE) reported Q3 revenue and losses, H.C. Wainwright analyst Andrew Fein issued thoughts on WVE-006 and WVE-007 and argued that shares remain “undervalued into a catalyst-ric...
Wave Life Sciences price target lowered to $29 from $32 at Oppenheimer
Oppenheimer analyst Cheng Li lowered the firm’s price target on Wave Life Sciences (WVE) to $29 from $32 and keeps an Outperform rating on the shares after the company reported…
Wave Life Sciences price target lowered to $23 from $30 at Jones
Jones analyst Catherine Novack lowered the firm’s price target on Wave Life Sciences (WVE) to $23 from $30 and keeps a Buy rating on the shares. The company reported Q3…
Wave Life Sciences price target lowered to $10 from $12 at Leerink
Leerink lowered the firm’s price target on Wave Life Sciences (WVE) to $10 from $12 and keeps an Outperform rating on the shares.
Wave Life Sciences Earnings Call Transcript: Q3 2026
Q3 revenue was $13.2M and cash resources of $431M are expected to fund operations into Q3 2028. Pipeline progress included WVE-007 Phase II-A studies, a planned single-trial WVE-006 registration path and a GSK siRNA candidate selection.
Wave Life Sciences Earnings release: Q3 2026
Wave Life Sciences released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Wave Life Sciences Quarterly report: Q3 2026
Wave Life Sciences has published its Q3 2026 quarterly earnings report on October 27, 2026.
Wave Life Sciences reports Q3 EPS (30c), consensus (32c)
Reports Q3 revenue $13.16M, consensus $4.39M. “We continue to make notable progress advancing our lead clinical programs. Following positive FDA feedback, planning is underway for our potentially regi...
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers
Wave Life Sciences Transcript: Chardan's 10th Annual Healthcare Conference
Single-dose Phase I WVE-007 data showed nearly 15% lower visceral fat, with lean mass preservation; Phase IIa studies are evaluating monotherapy, combination and maintenance uses. AAT editing showed consistent patient responses, with a two-year registrational trial and potential one-year interim analysis planned.
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences initiated with an Outperform at William Blair
William Blair initiated coverage of Wave Life Sciences (WVE) with an Outperform rating. Wave is a clinical-stage RNA medicines company advancing WVE-006 toward registrational development for AATD and ...
Wave Life Sciences initiated with a Buy at UBS
UBS initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $11 price target Wave is a leader in RNA editing therapeutic development with positive human proof of…
Wave Life Sciences Proxy statement: Proxy filing
Wave Life Sciences filed a proxy statement on October 14, 2026, providing details for shareholder voting and corporate governance matters.
Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences announces FDA feedback supports pathway for WVE-006
Wave Life Sciences (WVE) announced alignment with the U.S. Food and Drug Administration, FDA, on key aspects of its planned registrational pathway for WVE-006, an investigational GalNAc-RNA editing ol...
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
Wave Life Sciences initiated with a Buy at Ladenburg
Ladenburg analyst Rick Bienkowski initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $10 price target
Wave Life announces GSK’s selection of siRNA program to transition to GSK
Wave Life Sciences (WVE) announced that as part of the companies’ research collaboration, GSK (GSK) has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. ...
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
Wave Life Sciences resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Wave Life Sciences (WVE) with a Neutral rating and no price target Share upside will be tied to WVE-007 and if the drug can meet the…
Wave Life Sciences initiates Phase 2a combination trial of WVE-007
Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide in adults living with obesity. The...
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss c...